Background illustration for clinical trials search

Triple Negative Breast Cancer Clinical Trials

Browse 2,256 triple negative breast cancer clinical trials enrolling across the United States and Canada. Search by city or state to find one near you.

Filter
1

Docetaxel Followed by Capecitabine Versus Concomitant Docetaxel/Capecitabine for Early Stage Breast Cancer

for
Breast Neoplasms
Location: Atlanta GA
Sponsor: Georgia Center for Oncology Research & Education

Sex: Female

Age: 18+

Code: NCT00415285

Phase 2, Recruiting

TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery

for
Breast Adenocarcinoma, Stage II Breast Cancer AJCC v6 and v7,
Location: Lebanon NH, Pinehurst NC, Jacksonville FL,
Sponsor: Academic and Community Cancer Research United

Sex: Female

Age: 18+

Code: NCT04197687

Phase 2, Recruiting

A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies

for
KRAS G12C Mutation, KRAS G12S Mutation,
Location: Boston MA, Philadelphia PA, Fairfax VA, Jacksonville FL,
Sponsor: Kumquat Biosciences Inc.

Sex: All

Age: 18+

Code: NCT06720987

Phase 1, Recruiting

Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial

for
Locally Advanced Malignant Solid Neoplasm,
Location: Bethesda MD
Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT03907475

Phase 2, Recruiting

Wearable Activity Tracking to Curb Hospitalizations

for
Hematopoietic Neoplasm, Malignant Solid Neoplasm,
Location: San Francisco CA
Sponsor: University of California, San Francisco

Sex: All

Age: 18+

Code: NCT06587100

Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image

A Study of Therapeutic Iobenguane (131-I) and Vorinostat for Recurrent or Progressive High-Risk Neuroblastoma Subjects

for
Neuroblastoma, Neuroectodermal Tumors, Neoplasms
Location: Boston MA, New Hyde Park NY, New York NY,
Sponsor: Jubilant DraxImage Inc.

Sex: All

Age: 1+

Code: NCT03561259

Phase 2, Recruiting

The Effect of Epidural Fentanyl on Immune Function

for
Malignancy
Location: Montreal
Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre

Sex: All

Age: 18+

Code: NCT01646775

Recruiting

Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BTX-9341 in Advanced and/or Metastatic Breast Cancer

for
Breast Cancer
Location: Fairfax VA, Rochester MN, Omaha NE, Houston TX,
Sponsor: Biotheryx, Inc.

Sex: All

Age: 18+

Code: NCT06515470

Phase 1, Recruiting

A Clinical Trial to Assess COM503 in Participants With Advanced Solid Malignancies

for
Neoplasm, Cancer, Malignant Tumors
Location: Boston MA, New Haven CT, Fairfax VA, Grand Rapids MI,
Sponsor: Compugen Ltd

Sex: All

Age: 18+

Code: NCT06759649

Phase 1, Recruiting

SLV-154 Treatment of Advanced Cancers

for
Advanced Cancer, Advanced Solid Tumor, Metastatic Cancer
Location: New York NY, East Brunswick NJ, Philadelphia PA,
Sponsor: Solve Therapeutics

Sex: All

Age: 12+

Code: NCT06771219

Phase 1, Recruiting

ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR)

for
Locally Advanced Solid Tumor, Metastatic Solid Tumor
Location: Nashville TN, Dallas TX, Denver CO, San Diego CA
Sponsor: Acepodia Biotech, Inc.

Sex: All

Age: 18+

Code: NCT06415487

Phase 1, Recruiting

Cryoablation vs Lumpectomy in T1 Breast Cancers

for
Breast Cancer, Breast Neoplasm
Location: St Louis MO
Sponsor: Washington University School of Medicine

Sex: Female

Age: 50+

Code: NCT05505643

Recruiting

Intratumoral Delivery of Viral Replicon (saRNA) Particles Expressing IL-12 in Head and Neck Cancer

for
Head and Neck Cancers- Squamous Cell, Head and Neck Cancer,
Location: Stanford CA
Sponsor: VLP Therapeutics

Sex: All

Age: 18+

Code: NCT06736379

Phase 1, Recruiting

BRE-10: Biomarker Optimization of Neoadjuvant Therapy in Breast Cancer

for
Breast Cancer, HER2-positive Breast Cancer
Location: Chicago IL
Sponsor: University of Illinois at Chicago

Sex: All

Age: 18+

Code: NCT06441890

Phase 2, Recruiting

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)

for
Breast Cancer
Location: Providence RI, New Haven CT, Quebec, Stony Brook NY,
Sponsor: AstraZeneca

Sex: All

Age: 18+

Code: NCT06103864

Phase 3, Recruiting

Safety, Pharmacokinetics, and Clinical Activity of LP-284 in Adult Patients With Relapsed or Refractory Lymphomas and Solid Tumors

for
Relapsed or Refractory Lymphomas, Advanced Solid Tumor
Location: West Valley City UT
Sponsor: Lantern Pharma Inc.

Sex: All

Age: 18+

Code: NCT06132503

Phase 1, Recruiting

Pre-Operative Guided Meditation to Reduce Pre-Operative Anxiety in Patients Undergoing Cancer-Directed Surgery

for
Hematopoietic and Lymphatic System Neoplasm,
Location: Columbus OH
Sponsor: Ohio State University Comprehensive Cancer Center

Sex: All

Age: 18+

Code: NCT06949943

Recruiting

A Study of MGC026 in Participants With Advanced Solid Tumors

for
Advanced Solid Tumor, Advanced Cancer, Metastatic Cancer,
Location: Lake Success NY, Grand Rapids MI, Houston TX,
Sponsor: MacroGenics

Sex: All

Age: 18+

Code: NCT06242470

Phase 1, Recruiting

A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer

for
Locally Advanced Breast Cancer, Unresectable Breast Carcinoma,
Location: New York NY, Stony Brook NY, Chicoutimi, Uniondale NY,
Sponsor: BioNTech SE

Sex: All

Age: 18+

Code: NCT06827236

Phase 1, Phase 2, Recruiting

Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel

for
Neoplasms
Location: Bethesda MD
Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18 - 70+

Code: NCT04449549

Phase 2, Recruiting

What is triple negative breast cancer?

Triple negative breast cancer, or TNBC, is breast cancer whose cells test negative for estrogen receptors, progesterone receptors, and excess HER2 protein, so hormone therapy and HER2 targeted drugs do not work against it. It tends to grow faster and is more common in women who have not gone through menopause, in Black women, and in people with an inherited BRCA1 mutation, so genetic testing is recommended for everyone diagnosed. In US data, five year relative survival is about 92 percent when it is found while localized, 67 percent with regional spread, and 15 percent once it has reached distant organs. Standard treatment for early stage disease is chemotherapy combined with immunotherapy before surgery, followed by more treatment after; metastatic disease is treated with chemotherapy, immunotherapy for PD-L1 positive tumors, and antibody drug conjugates. Other breast cancers are covered on our breast cancer clinical trials page.

Types of triple negative breast cancer clinical trials

Who can participate in triple negative breast cancer clinical trials?

Is triple negative breast cancer hereditary?

Stages of triple negative breast cancer, and why they matter for trials

How to enroll in a triple negative breast cancer clinical trial